BioStock: Rising sales for newly listed Sensidose

Sensidose, active in Parkinson’s disease, reports its best sales figures to date in the company's history. Compared to the same period last year, sales increased by as much as 27 per cent. In addition, the company's cash position was recently strengthened by approximately 21.5 million SEK in connection with the listing on Spotlight Stock Market, which means that the company is equipped for continued growth.

Read the interview with Sensidose's CEO Jack Spira at biostock.se:

https://www.biostock.se/en/2022/05/rising-sales-for-newly-listed-sensidose/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/